Mint's pharma reporter Jessica Jani explores why India’s obsession with weight-loss shots is about more than just medicine.

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Novo Nordisk (NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human ...

BHVN’s investment case definitely weakened after Opakalim’s Phase 2 MDD miss. This also means they’ll discontinue their ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

The scientists discovered that if they block SCoR2, either through genetic changes or with a new drug, it prevents fat from ...

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

News you should know, including a really big Powerball jackpot; a salmonella outbreak linked to oysters; and more!

Obesity is a global epidemic and a major cause of morbidity and mortality because it increases the risk for comorbidities, ...

For the millions of Americans navigating the booming landscape of weight loss medications, the weekly injection routine just ...

Novo Nordisk's pill could be a convenient new option for adults seeking to lose weight. The worldwide market for weight-loss drugs could grow to a staggering $150 billion in the coming decade. The ...